announced today the launch of the dScreen Consortium, a research initiative
conducted with sanofi-aventis, Paris, and Louis Pasteur University of Strasbourg,
France, to develop the next generation of high-throughput screening (HTS) for
drug discovery applications. The consortium was founded with the assistance
of the ALSACE BIOVALLEY(TM) cluster, France, which helped secure financing and
support for the program. The expected gains in terms of productivity and knowledge
should accelerate the drug discovery programs.
The dScreen Consortium assembles the renowned drug screening expertise of sanofi-aventis,
the unique expertise in droplet-based micro reactors of the Chemical Biology
Laboratory at the Institute for Science and Supramolecular Engineering (ISIS)
in Louis Pasteur University, and RainDance Technologies' unique capabilities
to apply droplet-based microfluidic technologies to human health and disease
"We are delighted to enter this partnership with two highly innovative
research groups in this rapidly advancing field," said Martin Galvan Ph.D.,
Scientific Director at the sanofi-aventis research site in Strasbourg. "The
expected gains in terms of productivity and knowledge should significantly accelerate
our drug discovery programs."
Based in the Alsace Biovalley in Strasbourg, the consortium will utilize the
picoliter volumes and ultra-high-speed capabilities of RainDance's technology
and systems to achieve breakthrough performance in high-throughput drug screening
"This exciting project represents the first research collaboration undertaken
by our new RainDance Technologies France SARL subsidiary," said Chris McNary,
President and Chief Executive Officer of RainDance Technologies. "The simplicity,
speed and minute volume of our technology replace current complex automation
solutions in high-throughput screening. Our technology will process 10 million
droplets per hour on a single benchtop instrument, dramatically accelerating
the drug discovery process while conserving precious screening compounds,"
"This project is an excellent opportunity to develop the compartmentalisation
of reactions in emulsion droplets for an entirely new field of application:
HTS for drug discovery," said Andrew Griffiths, head of the Chemical Biology
Laboratory at ISIS.
"The dScreen Consortium is a great illustration of the 'Pole de Competitivite'
policy in France: the development of breakthrough innovations in drug screening
through collaborative R&D programs results in strengthening local actors
such as the sanofi-aventis research site and in the creation of a U.S. subsidiary
company in Alsace. Furthermore, the establishment of a drug screening services
platform based on the results of the program will reinforce the capabilities
of our cluster," said Pascal Neuville, President of ALSACE BIOVALLEY.